Metabolic dysfunction-associated steatotic liver disease as a risk factor for cognitive decline: Findings from the ELSA-Brasil cohort.

ABSTRACT:

Introduction

Metabolic dysfunction-associated steatotic liver disease (MASLD) has been linked to adverse brain outcomes. We aim to evaluate whether MASLD is associated with cognitive impairment/decline.

Methods

We analyzed data from the Estudo Longitudinal da Saúde do Adulto (ELSA-Brasil study). Global cognitive performance was assessed at baseline and follow-up. Associations between MASLD and cognition were tested using Poisson regression and linear mixed-effects models (LMMs).

Results

MASLD was present in 13.6% (n = 918/6754) of participants at baseline. MASLD was not associated with incident cognitive impairment (Relative Risk: 1.01; 95% confidence interval [CI]: 0.83-1.23; p = 0.91). In LMMs, in a fully adjusted model, MASLD was not associated with cognitive decli

SUBMITTER: Castilhos RM 

PROVIDER: S-EPMC12815608 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature